Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Stephen Ferrière, Ivan Peyron, Olivier D. Christophe, Charlotte Kawecki, Caterina Casari, Vincent Muczynski, Amit Nathwani, Alexandre Kauskot, Peter J. Lenting, Cécile V. Denis

Blood (2020) 136 (6): 740–748.

https://doi.org/10.1182/blood.2019004334

Published: 2020

Includes: Supplemental data

Journal Articles

How much clotting is enough?

Laurent O. Mosnier

Blood (2020) 136 (6): 651–652.

https://doi.org/10.1182/blood.2020006443

Published: 2020

Journal Articles

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Guy Young, Ri Liesner, Tiffany Chang, Robert Sidonio, Jr, Johannes Oldenburg, Victor Jiménez-Yuste, Johnny Mahlangu, Rebecca Kruse-Jarres, Michael Wang, Marianne Uguen, Michelle Y. Doral, Lilyan Y. Wright, Christophe Schmitt, Gallia G. Levy, Midori Shima, Maria Elisa Mancuso

Blood (2019) 134 (24): 2127–2138.

https://doi.org/10.1182/blood.2019001869

Published: 2019

Includes: Supplemental data

Journal Articles

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Anna Kiialainen, PhD, Markus Niggli, PhD, Christine L. Kempton, MD MSc, Giancarlo Castaman, MD, Tiffany Y. Chang, MD MAS, Ido Paz-Priel, MD, Joanne I Adamkewicz, PhD, Gallia G. Levy, MD PhD

Blood (2019) 134 (Supplement_1): 626.

https://doi.org/10.1182/blood-2019-123689

Published: 2019

Journal Articles

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Nicholas B George, MD, Alexander Paschke, Katie Scott, MD

Blood (2019) 134 (Supplement_1): 4938.

https://doi.org/10.1182/blood-2019-127105

Published: 2019

Journal Articles

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Wendy E. Owens, MA, Anisha M. Patel, PhD, Kathleen Poulos, RN, Janet Bernard, BA, Janet Powers, MPH, MBA, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 4941.

https://doi.org/10.1182/blood-2019-123730

Published: 2019

Journal Articles

Characteristics of Hemophilia A Patients Treated with Emicizumab: an Early View using Claims Database Analysis

Arash Mahajerin, MD MS, Erru Yang, MS, Anisha M. Patel, PhD

Blood (2019) 134 (Supplement_1): 4928.

https://doi.org/10.1182/blood-2019-123724

Published: 2019

Journal Articles

Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center

Susan U Lattimore, Madolyn T Hofstetter, BS

Blood (2019) 134 (Supplement_1): 5796.

https://doi.org/10.1182/blood-2019-131030

Published: 2019

Journal Articles

Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey

Hanny Al-Samkari, MD, Stacy E. Croteau

Blood (2019) 134 (Supplement_1): 3395.

https://doi.org/10.1182/blood-2019-125364

Published: 2019

Journal Articles

A Novel Approach for Generating Platelet-Delivered FVIII: Role of Transient LRP1 Expression during Megakaryopoiesis

John Tkaczynski, BS, Randolph Lyde, PhD, Hyunsook Ahn, MSc, Francis Ayombil, PhD, Sara Borst, BS, Paul Gadue, PhD, Deborah L French, PhD, Denise Sabatino, PhD, Rodney M. Camire, PhD, Mortimer Poncz, MD

Blood (2019) 134 (Supplement_1): 1102.

https://doi.org/10.1182/blood-2019-124788

Published: 2019

Journal Articles

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Hande Kizilocak, Elizabeth Marquez-Casas, BS, Jemily Malvar, MS, Roxana Carmona, MD, Guy Young, MD

Blood (2019) 134 (Supplement_1): 1134.

https://doi.org/10.1182/blood-2019-123820

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Viola J.F. Strijbis, MSc, Ka Lei Cheung, Pavlina Konstantinova, PhD, Ying Poi Liu, PhD, Sander J van Deventer, MD PhD, Mettine H.A. Bos, PhD

Blood (2019) 134 (Supplement_1): 1110.

https://doi.org/10.1182/blood-2019-124120

Published: 2019

Journal Articles

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

Ihosvany Fernandez-Bello, María Teresa Alvarez Román, Mónica Martín, María Isabel Rivas Pollmar, Sara García Barcenilla, Carmen García Martínez, Tamara Cebanu, Paula Acuña, Raul Justo Sanz, Elena Monzón Manzano, Miguel A Canales, MD PhD, Nora Butta, PhD, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1118.

https://doi.org/10.1182/blood-2019-129983

Published: 2019

Journal Articles

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

Tom Knudsen, PhD DVM, Brajesh Kumar, Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 1112.

https://doi.org/10.1182/blood-2019-130559

Published: 2019

Journal Articles

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Amelia R. Wilhelm, B.S., Nicole A. Parsons, B.S., Charles T. Esmon, PhD, Rodney M. Camire, PhD, Lindsey A. George, MD

Blood (2019) 134 (Supplement_1): 93.

https://doi.org/10.1182/blood-2019-124493

Published: 2019

Journal Articles

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Blood (2019) 134 (Supplement_1): 96.

https://doi.org/10.1182/blood-2019-122817

Published: 2019

Journal Articles

Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins

Tiffany Lin Lucas, MD, Shveta Gupta, MBBS, Joanna A. Davis, MD, Fernando F. Corrales-Medina, MD

Blood (2019) 134 (Supplement_1): 2409.

https://doi.org/10.1182/blood-2019-127270

Published: 2019

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

A hemophilia A mouse model for the in vivo assessment of emicizumab function

How much clotting is enough?

A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors

Bone and Joint Health Markers in Persons with Hemophilia A (PwHA) Treated with Emicizumab in HAVEN 3

Central Line-Associated Thrombus Formation in an Inhibitor Negative Severe Hemophilia A Patient on Emicizumab

Characterization and Disease Management of Persons with Hemophilia A Treated with Emicizumab: A Survey Study of Hematologists in the US

Characteristics of Hemophilia A Patients Treated with Emicizumab: an Early View using Claims Database Analysis

Patient and Family Engagement during Treatment Change to Emicizumab at a Hemophilia Treatment Center

Beliefs, Opinions, and Impact of Emicizumab on Hemophilia Patients: A National U.S. Survey

A Novel Approach for Generating Platelet-Delivered FVIII: Role of Transient LRP1 Expression during Megakaryopoiesis

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Evaluation of a Blood Coagulation Factor IX Variant That Functions Independently of Factor VIII As an Alternative Treatment for Hemophilia A

Evaluation of the in Vitro Procoagulant Effect of Factor IX Concentrates in Patients on Prophylaxis with Emicizumab

The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable As Assessed By the Thrombin Generation Test in Hemophilia a Plasma

In Vivo hemostatic Significance of Activated Protein C in Factor VIIIa Regulation

Mim8 - a Next-Generation FVIII Mimetic Bi-Specific Antibody - Potently Restores the Hemostatic Capacity in Hemophilia a Settings in Vitro and In Vivo

Emicizumab-Kxwh for Previously Untreated Patients with Haemophilia: The Conversation Begins

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only